Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 3/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.33 |
| ▸ | PNMT | P11086 | 1/20 | 0.33 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.31 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.31 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.31 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.31 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.31 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1021592 | 1.00 | CA2 (0.41) | CA2PTGS2HTR6HTR1AFFAR1 | |
| SCHEMBL1880646 | 0.87 | CA2 (0.43) | CA2PTGS2HTR6FFAR1BRD4 | |
| SCHEMBL1884064 | 0.85 | HTR6 (0.50) | CA2PTGS2HTR6 | |
| SCHEMBL1884843 | 0.85 | CA2 (0.39) | CA2PTGS2HTR6BRD4PTGS1 | |
| SCHEMBL1882531 | 0.85 | HTR6 (0.50) | CA2PTGS2HTR6 | |
| SCHEMBL1019050 | 0.85 | CA2 (0.43) | CA2HTR6 | |
| SCHEMBL1883681 | 0.84 | CA2 (0.38) | CA2PTGS2HTR6HTR1AFFAR1 | |
| SCHEMBL1884190 | 0.84 | CA2 (0.39) | CA2PTGS2HTR6FFAR1BRD4 | |
| SCHEMBL1080215 | 0.83 | CA2 (0.46) | CA2HTR6 | |
| SCHEMBL1889166 | 0.83 | CA2 (0.46) | CA2HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2271634-B1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | INTEGRATIVE RES LAB SWEDEN AB (SE) | 2014-02-12 | — | — | EP | disclosed |
| US-8524766-B2 | Modulators of dopamine neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2013-09-03 | — | — | US | disclosed |
| US-20110105461-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2011-05-05 | — | — | US | disclosed |
| EP-2271634-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009133107-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105461-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | DBH, SLC18A2, SLC6A3 | CA2 3728/4885PTGS2 1864/4885HTR6 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.